US2020230217A1PendingUtilityA1
Methods for treating headache
Est. expiryFeb 26, 2024(expired)· nominal 20-yr term from priority
A61K 38/48A61K 39/08A61P 29/00C12Y 304/24069A61K 38/4893A61P 25/30A61P 43/00A61P 25/06A61P 25/00A61P 25/08A61K 9/0019
74
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . A method for reducing the occurrence or alleviating a headache in a patient in need thereof, the method comprising local administration by injection of a composition comprising a botulinum toxin type A, wherein the number of injection sites is 23 to 58, the number of muscle areas injected is 6 to 7 and the botulinum toxin type A dose is 105 to 260 units, and wherein at least the frontal/glabellar, occipitalis, temporalis, semispinalis, splenius capitis or trapezius muscles are injected.
2 . The method of claim 1 , wherein the headache is a migraine headache.
3 . The method of claim 1 , wherein the headache is a non-migraine headache.
4 . The method of claim 3 , wherein the administration is subdermal or subcutaneous.
5 . The method of claim 1 , wherein the administration is intramuscular.
6 . The method of claim 1 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C 1 , D, E, F and G.
7 . The method of claim 1 , wherein the botulinum toxin is a botulinum toxin type A.Join the waitlist — get patent alerts
Track US2020230217A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.